Combining metabolic intervention with T-cell immunotherapy is safe and resulted in improved efficacy in two mouse models of solid tumors, providing an alternative combination strategy for boosting ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Back to Healio The FDA cleared an investigational new ...
Liposomal gemcitabine in combination with pembrolizumab shows promise in the treatment of advanced solid tumors, according to a study presented at the recent American Society of Clinical Oncology ...
Recent advances in cancer biology have led to the discovery and development of chemical compounds and drugs that target specific cellular receptors, mediators, or effectors that are central to ...
Overall, 14 patients were recruited in part 1 and 238 in part 2. In part 1, the maximum tolerated dose of the combination was not reached; the RP2D was BI 836880 720 mg plus ezabenlimab 240 mg every 3 ...
– Both single-agent XL092 and XL092 in combination with atezolizumab demonstrated encouraging efficacy and safety in a heavily pretreated patient population – – XL092 demonstrated preliminary clinical ...
FRAME study demonstrated a 42.3% ORR and 20.1 months median PFS for all patients with low-grade serous ovarian cancer (LGSOC), regardless of KRAS mutation; for patients with KRAS-mutated LGSOC, ORR ...
Adrian Rawcliffe, Adaptimmune’s Chief Executive Officer: “This strategic combination takes two technologically and culturally aligned companies at the forefront of their fields and combines them to ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback